Urothelial Carcinoma and Bladder Cancer Management Strategies

Urothelial carcinoma accounts for the vast majority of bladder cancers and presents along a continuum from non-muscle-invasive lesions to muscle-invasive and metastatic disease. Non-muscle-invasive bladder cancer (NMIBC) is typically managed by transurethral resection followed by intravesical therapy and close surveillance, aiming to prevent progression while preserving the bladder. Muscle-invasive bladder cancer (MIBC) often requires radical cystectomy combined with neoadjuvant platinum-based chemotherapy or trimodal bladder-sparing protocols. In the advanced setting, systemic therapy has evolved from cytotoxic regimens to immune checkpoint inhibitors and antibody–drug conjugates, ushering in a new era of biomarker-guided precision treatments. Molecular classification of tumours has refined patient stratification, guiding FGFR3-targeted agents and combination immunotherapies. Concurrent research seeks to optimise organ preservation, reduce treatment morbidity and integrate real-time biomarkers from the tumour microenvironment to predict response. Globally, prevention through smoking cessation, environmental control and early detection programmes remains critical to reduce incidence and improve outcomes.

Research from Nature Portfolio

Recent clinical trials have demonstrated that combining gemcitabine and cisplatin with a PD-1 inhibitor can achieve high rates of clinical complete response in MIBC, enabling a substantial proportion of patients to defer or avoid radical cystectomy while maintaining favourable two-year metastasis-free survival. This organ-sparing approach is prompting further investigation into patient selection and long-term functional outcomes.

Analyses of bulk transcriptomes have revealed that stromal-cell-derived epithelial–mesenchymal transition (EMT) signatures can undermine the efficacy of PD-1 blockade in urothelial carcinoma. Tumours with high EMT-related stromal content show reduced progression-free survival despite T-cell infiltration, suggesting that co-targeting stromal elements alongside immune checkpoints may overcome microenvironment-mediated resistance.

Urothelial Carcinoma and Bladder Cancer Management Strategies publication trend

The graph below shows the total number of articles in urothelial carcinoma and bladder cancer management strategies across all publications each year (not limited to Nature Index journals).

Technical terms

Urothelial carcinoma: A malignancy arising from the urothelial lining of the bladder, ureters or renal pelvis.

Non-muscle-invasive bladder cancer (NMIBC): Tumours confined to the mucosa or lamina propria that have not invaded the detrusor muscle.

Muscle-invasive bladder cancer (MIBC): Tumours that penetrate into or beyond the muscular layer of the bladder wall, with higher metastatic potential.

Immune checkpoint inhibitors (ICIs): Antibodies that block inhibitory receptors or ligands (e.g. PD-1/PD-L1) to enhance anti-tumour T-cell activity.

Clinical complete response (cCR): The absence of detectable tumour by clinical and radiological assessment following therapy.

Tumour microenvironment (TME): The cellular milieu surrounding cancer cells, including immune, stromal and vascular components that influence tumour behaviour.

Antibody–drug conjugate (ADC): A targeted therapy comprising an antibody linked to a cytotoxic agent, delivering chemotherapy directly to antigen-expressing tumour cells.

References

1. Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial. Nature Medicine (2023).
2. The Impact of FGFR3 Alterations on the Tumor Microenvironment and the Efficacy of Immune Checkpoint Inhibitors in Bladder Cancer. Molecular Cancer (2023).
3. Epidemiology of Bladder Cancer. Medical Sciences (2020).
4. EMT- and stroma-related gene expression and resistance to PD-1 blockade in urothelial cancer. Nature Communications (2018).
5. EV-101: A Phase I Study of Single-Agent Enfortumab Vedotin in Patients With Nectin-4–Positive Solid Tumors, Including Metastatic Urothelial Carcinoma. Journal of Clinical Oncology (2020).
6. Siglec15 shapes a non-inflamed tumor microenvironment and predicts the molecular subtype in bladder cancer. Theranostics (2021).